⌘K
Loading ticker…
Exelixis Inc · Healthcare · Pharmaceutical Products
As of 2026-06-26, Exelixis Inc (EXEL) has a 3-month relative strength percentile of 80 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 58. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 3.1%, relative volume 2.60×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 80, Market Stance is mixed at 47, A/D rating C
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
EXEL is in a stage 2 uptrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 11.1% / 24.9%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
EXEL is held by 13 ETFs as of Mar 2026. Top owner: IJH at 0.35% weight, $369M notional. Top 3 carry $950M.
Top 10 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IJHiShares Core S&P Mid-Cap ETF | 0.35% | $369M |
| VTIVanguard Total Stock Market ETF | 0.02% | $337M |
| VBVanguard Small Cap ETF | 0.15% | $244M |
| VBKVanguard Small-Cap Growth ETF | 0.35% | $137M |
| VXFVanguard Extended Market ETF | 0.15% | $124M |
| XBIState Street SPDR S&P Biotech ETF | 1.17% | $87M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | 0.35% | $84M |
| IWRiShares Russell Midcap ETF | 0.09% | $43M |
| IWFiShares Russell 1000 Growth ETF | 0.03% | $37M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.02% | $14M |
Showing 10 of 13 ETF owners.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EXEL Jan avg: -1.38% median: -3.04% win: 25% σ: 8.32% n: 4 2022-04-12 → 2026-05-29 | EXEL Feb avg: 5.21% median: 3.59% win: 75% σ: 8.63% n: 4 2022-04-12 → 2026-05-29 | EXEL Mar avg: 3.69% median: 2.85% win: 50% σ: 8.74% n: 4 2022-04-12 → 2026-05-29 | EXEL Apr avg: 0.52% median: -0.22% win: 40% σ: 4.54% n: 5 2022-04-12 → 2026-05-29 | EXEL May avg: 0.67% median: 5.36% win: 60% σ: 13.11% n: 5 2022-04-12 → 2026-05-29 | EXEL Jun avg: 4.68% median: 3.00% win: 75% σ: 6.23% n: 4 2022-04-12 → 2026-05-29 (current) | EXEL Jul avg: -2.46% median: 1.81% win: 75% σ: 10.37% n: 4 2022-04-12 → 2026-05-29 | EXEL Aug avg: 3.18% median: 7.16% win: 75% σ: 13.01% n: 4 2022-04-12 → 2026-05-29 | EXEL Sep avg: -0.99% median: -1.36% win: 25% σ: 9.03% n: 4 2022-04-12 → 2026-05-29 | EXEL Oct avg: 5.39% median: -0.01% win: 50% σ: 16.03% n: 4 2022-04-12 → 2026-05-29 | EXEL Nov avg: 8.25% median: 7.87% win: 100% σ: 4.86% n: 4 2022-04-12 → 2026-05-29 | EXEL Dec avg: -1.38% median: -3.43% win: 25% σ: 8.27% n: 4 2022-04-12 → 2026-05-29 |